Benitec welcomes independent research findings

Company News

Benitec Biopharma Limited (ASX:BLT) has welcomed publications of independent research supporting Tribetarna for additional cancer indications. 
The biotechnology company believes the findings from universities in Sydney and Germany provide potential for its Tribetarna program to expand beyond lung cancer. 
CEO and Managing Director Dr Peter French says it is pleasing to see Beneitec’s target gene for non-small cell lung cancer being implicated in an ever-widening range of solid cancers. 
The news comes in the same week Benitec advised a third patient in the clinical trial of its TT-034 treatment of Hepatitis C has been dosed and the results are set for review in six weeks. 
Benitec Biopharma reported a net loss of $7.03 million in the 2014 financial year. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.